514 related articles for article (PubMed ID: 31561209)
1. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
Taïeb D; Jha A; Treglia G; Pacak K
Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209
[TBL] [Abstract][Full Text] [Related]
2. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
3. Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma.
Taïeb D; Pacak K
Cell Tissue Res; 2018 May; 372(2):393-401. PubMed ID: 29450723
[TBL] [Abstract][Full Text] [Related]
4. Performance of
Han S; Suh CH; Woo S; Kim YJ; Lee JJ
J Nucl Med; 2019 Mar; 60(3):369-376. PubMed ID: 30030341
[TBL] [Abstract][Full Text] [Related]
5. PET detectives: Molecular imaging for phaeochromocytomas and paragangliomas in the genomics era.
Ryder SJ; Love AJ; Duncan EL; Pattison DA
Clin Endocrinol (Oxf); 2021 Jul; 95(1):13-28. PubMed ID: 33296100
[TBL] [Abstract][Full Text] [Related]
6. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
7. Pheochromocytomas and paragangliomas.
Yen K; Lodish M
Curr Opin Pediatr; 2021 Aug; 33(4):430-435. PubMed ID: 34039901
[TBL] [Abstract][Full Text] [Related]
8.
Feral CC; Tissot FS; Tosello L; Fakhry N; Sebag F; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):812-821. PubMed ID: 27900521
[TBL] [Abstract][Full Text] [Related]
9. Role of imaging test with radionuclides in the diagnosis and treatment of pheochromocytomas and paragangliomas.
Araujo-Castro M; Pascual-Corrales E; Alonso-Gordoa T; Molina-Cerrillo J; Martínez Lorca A
Endocrinol Diabetes Nutr (Engl Ed); 2022 Oct; 69(8):614-628. PubMed ID: 36402734
[TBL] [Abstract][Full Text] [Related]
10. Integrated PET/MRI With 68Ga-DOTATATE and 18F-FDG in Pheochromocytomas and Paragangliomas: An Initial Study.
Xu S; Pan Y; Zhou J; Ju H; Zhang Y
Clin Nucl Med; 2022 Apr; 47(4):299-304. PubMed ID: 35143455
[TBL] [Abstract][Full Text] [Related]
11. New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.
Taïeb D; Pacak K
Trends Endocrinol Metab; 2017 Nov; 28(11):807-817. PubMed ID: 28867159
[TBL] [Abstract][Full Text] [Related]
12. PHEOCHROMOCYTOMA: A GENETIC AND DIAGNOSTIC UPDATE.
Mercado-Asis LB; Wolf KI; Jochmanova I; Taïeb D
Endocr Pract; 2018 Jan; 24(1):78-90. PubMed ID: 29144820
[TBL] [Abstract][Full Text] [Related]
13. Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation.
Abdul Sater Z; Jha A; Hamimi A; Mandl A; Hartley IR; Gubbi S; Patel M; Gonzales M; Taïeb D; Civelek AC; Gharib AM; Auh S; O'Mara AE; Pacak K; Cypess AM
J Clin Endocrinol Metab; 2020 Apr; 105(4):1176-85. PubMed ID: 31903484
[TBL] [Abstract][Full Text] [Related]
14. Genetic Determinants of Pheochromocytoma and Paraganglioma Imaging Phenotypes.
Taïeb D; Pacak K
J Nucl Med; 2020 May; 61(5):643-645. PubMed ID: 32198315
[TBL] [Abstract][Full Text] [Related]
15. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
16. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
[TBL] [Abstract][Full Text] [Related]
17.
Krokhmal AA; Kwatra N; Drubach L; Weldon CB; Janeway KA; DuBois SG; Kamihara J; Voss SD
Pediatr Blood Cancer; 2022 Aug; 69(8):e29740. PubMed ID: 35484995
[TBL] [Abstract][Full Text] [Related]
18. Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview.
De Filpo G; Maggi M; Mannelli M; Canu L
J Endocrinol Invest; 2021 Jan; 44(1):15-25. PubMed ID: 32602077
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.
Patel M; Tena I; Jha A; Taieb D; Pacak K
Front Endocrinol (Lausanne); 2021; 12():625312. PubMed ID: 33854479
[TBL] [Abstract][Full Text] [Related]
20. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials.
Severi S; Bongiovanni A; Ferrara M; Nicolini S; Di Mauro F; Sansovini M; Lolli I; Tardelli E; Cittanti C; Di Iorio V; Mezzenga E; Scarpi E; Ibrahim T; Paganelli G; Zovato S
ESMO Open; 2021 Aug; 6(4):100171. PubMed ID: 34139487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]